Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

NCT07533305 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

QL1706
ESCC
First-line Therapy

Interventions

DRUG: QL1706 plus nab-paclitaxel and cisplatin

Sponsor

The First Affiliated Hospital of Henan University of Science and Technology